Seclidemstat and Azacitidine for the Treatment of Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
Key claim: A phase I/II trial is evaluating the optimal dose and efficacy of seclidemstat combined with azacitidine in patients with myelodysplastic syndrome or chronic myelomonocytic leukemia.
Abstract
This phase I/II trial identifies the best dose of seclidemstat when given together with azacitidine in treating patients with myelodysplastic syndrome or chronic myelomonocytic leukemia. Seclidemstat may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Azacitidine may help block the formation of growths that may become cancer. Giving seclidemstat and azacytidine may kill more cancer cells.
Why this matters
Seclidemstat is the first LSD1/KDM1A inhibitor to be combined with azacitidine prospectively in MDS/CMML, opening a new epigenetic axis (histone demethylase inhibition) on top of the established HMA backbone for these subtypes. For CMML specifically — where treatment options remain limited and HMA-refractory disease is a major unmet need — this trial broadens the mechanistic landscape beyond BCL-2, FLT3, and IDH1 directed strategies already in development.